/ /

Mari Edlin
Mari Edlin is a frequent contributor to Managed Healthcare Executive. She is based in Sonoma, California.
Controversy surrounds Exondys 51 approval: What to know
New medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.
Four health systems develop opioid mitigation programs
Alternatives to opioids programs emerge as viable tools to mitigate the crisis.
Value-based drug contracting shifts risk to manufacturers
Value-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
Autoimmune drug pipeline: What health execs should watch
New drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Five imitation-worthy palliative care programs
Here's how five health plans are successfully approaching palliative care.
Prevent polypharmacy problems
Polypharmacy presents real problems—especially for older adults.
New strategies for managing drug spend: RA, Cancer, Hep C
New strategies for managing drug spend: RA, Cancer, Hep C
The proliferation of specialty drugs has prompted new techniques for keeping costs in tow.
Watch list 2017: Top therapeutic areas
Watch list 2017: Top therapeutic areas
Find out about the latest treatment and drug pipeline developments
Top pharmacy challenges of 2017
Top pharmacy challenges of 2017
High drug prices continue to plague payers, but various contributing factors intensify the problem.
Four innovative models rein in pharma costs
Four innovative models rein in pharma costs
Plans and PBMs are finding new ways to rein in pharmacy costs.

Poll

View Results